×
About 1,392 results

Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31042-4/fulltext
The Lancet;

Effective antiviral therapy is important for tackling the coronavirus disease 2019 (COVID-19) pandemic. We assessed the efficacy and safety of combined interferon beta-1b, lopinavir–ritonavir, and ribavirin for treating patients with COVID-19.

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China
https://jamanetwork.com/journals/jamacardiology/fullarticle/2763524
JAMA Cardiology;

Importance Coronavirus disease 2019 (COVID-19) has resulted in considerable morbidity and mortality worldwide since December 2019. However, information on cardiac injury in patients affected by COVID-19 is limited. Objective To explore the association between cardiac injury and mortality in patients with COVID-19. Design, Setting, and Participants This cohort study was conducted...

Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Remdesivir (GS-5734™)
https://www.fda.gov/media/137566/download

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product remdesivir for treatment of suspected or laboratory confirmed coronavirus disease 2019 (COVID-19) in adults and children hospitalized with severe disease. Severe disease is defined as patients with an oxygen saturation (SpO2) ≤ 94% ...

Abiomed Impella RP - FDA Letter of Authorization
https://www.fda.gov/media/138460/download

This letter is in response to your request that the Food and Drug Administration (FDA) issue an Emergency Use Authorization (EUA) for emergency use of the Impella RP System1 (hereafter “Impella RP”) intended to be used by healthcare providers (HCP) in the hospital setting for providing temporary right ventricular support for up to 14 days in critical care patients2 with a body surface area ...

Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with Coronavirus Disease 2019 (COVID-19)
https://emergency.cdc.gov/han/2020/han00432.asp

The Centers for Disease Control and Prevention (CDC) is providing 1) background information on several cases of a recently reported multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19); and 2) a case definition for this syndrome. CDC recommends healthcare providers report any patient who meets the case definition to local, state, and t...

Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19)
https://www.mja.com.au/system/files/issues/212_09/mja250577.pdf

Lung Health & Diseases: Coronavirus Disease (COVID-19)
https://www.lung.org/lung-health-diseases/lung-disease-lookup/covid-19

COVID-19 is a lung disease caused by a novel coronavirus first detected in late 2019. COVID-19 and its symptoms can range from mild to severe. Anyone can get COVID-19, but some individuals are more at risk for severe disease than others. There is currently no specific treatment other than supportive care available. The majority of people recover from COVID-19 within a few weeks, b...

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7159299
Lancet (London, England); Huang C, Wang Y et. al.

Jan 27th, 2020 - A recent cluster of pneumonia cases in Wuhan, China, was caused by a novel betacoronavirus, the 2019 novel coronavirus (2019-nCoV). We report the epidemiological, clinical, laboratory, and radiological characteristics and treatment and clinical outcomes of these patients. All patients with suspected 2019-nCoV were admitted to a designated hospital in Wuhan. We prospectively...

Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosi...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526251
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America; Hirsch HH, Martino R et. al.

Oct 1st, 2012 - Community-acquired respiratory virus (CARV) infections have been recognized as a significant cause of morbidity and mortality in patients with leukemia and those undergoing hematopoietic stem cell transplantation (HSCT). Progression to lower respiratory tract infection with clinical and radiological signs of pneumonia and respiratory failure appears to depend on the intrinsic virulence of the s...

Deep Vein Thrombosis in Hospitalized Patients with Coronavirus Disease 2019 (COV...
https://doi.org/10.1161/CIRCULATIONAHA.120.046702
Circulation Zhang L, Feng X et. al.

May 18th, 2020 - Background: To investigate deep vein thrombosis (DVT) in hospitalized patients with coronavirus disease 2019 (COVID-19), we performed a single institutional study to evaluate its prevalence, risk factors, prognosis, and potential thromboprophylaxis strategies in a large referral and treatment center. Methods: We studied a total of 143 patients with COVID-19 from January 29 to Febr...

A Systematic Review of therapeutic agents for the treatment of the Middle East R...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110863
Travel Medicine and Infectious Disease; Momattin H, Al-Ali AY et. al.

Jun 29th, 2019 - The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) was first described in 2012 and attracted a great international attention due to multiple healthcare associated outbreaks. The disease carries a high case fatality rate of 34.5%, and there is no internationally or nationally recommended therapy. We searched MEDLINE, Science Direct, Embase and Scopus databases for relevant papers...

A systematic review of lopinavir therapy for SARS coronavirus and MERS corona...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217143
Journal of Medical Virology; Yao TT, Qian JD et. al.

Feb 27th, 2020 - In the past few decades, coronaviruses have risen as a global threat to public health. Currently, the outbreak of coronavirus disease-19 (COVID-19) from Wuhan caused a worldwide panic. There are no specific antiviral therapies for COVID-19. However, there are agents that were used during the severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) epide...

Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disea...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262196
Pharmacotherapy Barlow A, Landolf KM et. al.

Apr 7th, 2020 - The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved into an emergent global pandemic. Coronavirus disease 2019 (COVID-19) can manifest on a spectrum of illness from mild disease to severe respiratory failure requiring intensive care unit admission. As the incidence continues to rise at a rapid pace, critical care teams are faced with challengin...

Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaqu...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7104368
Proceedings of the National Academy of Sciences of the United States of America; de Wit E, Feldmann F et. al.

Feb 14th, 2020 - The continued emergence of Middle East Respiratory Syndrome (MERS) cases with a high case fatality rate stresses the need for the availability of effective antiviral treatments. Remdesivir (GS-5734) effectively inhibited MERS coronavirus (MERS-CoV) replication in vitro, and showed efficacy against Severe Acute Respiratory Syndrome (SARS)-CoV in a mouse model. Here, we tested the e...

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101507
JAMA Shen C, Wang Z et. al.

Mar 28th, 2020 - Coronavirus disease 2019 (COVID-19) is a pandemic with no specific therapeutic agents and substantial mortality. It is critical to find new treatments. To determine whether convalescent plasma transfusion may be beneficial in the treatment of critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Case series of 5 critical...

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211500
Lancet (London, England); Hung IF, Lung KC et. al.

May 13th, 2020 - Effective antiviral therapy is important for tackling the coronavirus disease 2019 (COVID-19) pandemic. We assessed the efficacy and safety of combined interferon beta-1b, lopinavir-ritonavir, and ribavirin for treating patients with COVID-19. This was a multicentre, prospective, open-label, randomised, phase 2 trial in adults with COVID-19 who were admitted to six hospitals in Hong Kong...

Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospita...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7215635
JAMA Rosenberg ES, Dufort EM et. al.

May 11th, 2020 - Hydroxychloroquine, with or without azithromycin, has been considered as a possible therapeutic agent for patients with coronavirus disease 2019 (COVID-19). However, there are limited data on efficacy and associated adverse events. To describe the association between use of hydroxychloroquine, with or without azithromycin, and clinical outcomes among hospital inpatients diagnosed with CO...

Effective treatment of severe COVID-19 patients with tocilizumab.
https://doi.org/10.1073/pnas.2005615117
Proceedings of the National Academy of Sciences of the United States of America; Xu X, Han M et. al.

Apr 30th, 2020 - After analyzing the immune characteristics of patients with severe coronavirus disease 2019 (COVID-19), we have identified that pathogenic T cells and inflammatory monocytes with large amount of interleukin 6 secreting may incite the inflammatory storm, which may potentially be curbed through monoclonal antibody that targets the IL-6 pathways. Here, we aimed to assess the efficacy of toc...

Ribavirin and interferon-α2b as primary and preventive treatment for Middle East...
https://doi.org/10.3851/IMP2792
Antiviral Therapy; Khalid M, Al Rabiah F et. al.

May 16th, 2014 - Middle East respiratory syndrome coronavirus (MERS-CoV) is a newly recognized transmissible viral infection with high virulence and case fatality rates for which there is no currently defined primary treatment or prophylaxis. Saudi Arabia has the largest reported number of cases so far. Like severe acute respiratory syndrome (SARS), MERS is caused by a coronavirus. Combinat...

Treatment outcomes for patients with Middle Eastern Respiratory Syndrome Coro...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839124
BMC Infectious Diseases; Al Ghamdi M, Alghamdi KM et. al.

Apr 21st, 2016 - Middle Eastern Respiratory Syndrome coronavirus (MERS-CoV) is a poorly understood disease with no known treatments. We describe the clinical features and treatment outcomes of patients with laboratory confirmed MERS-CoV at a regional referral center in the Kingdom of Saudi Arabia. In 2014, a retrospective chart review was performed on patients with a laboratory confirmed di...